This pathomechanism is relevant to major depression where about one third of cases have an inflammatory phenotype with CRP levels >3 mg/L and respond to infliximab, a monoclonal antibody that antagonizes tumor necrosis factor alpha (TNFa; Treadway et al., 2024). Here, CRP is linked to major depressive disorder.